U.S. Markets open in 6 hrs 33 mins

EDAP TMS S.A. (EDAP)

NASDAQ Global Market - NASDAQ Global Market Delayed Price. Currency in USD
Add to watchlist
2.62-0.06 (-2.24%)
At close: 3:59PM EDT
People also watch
DYNTDRADESMCIRIXELGX
  • s
    silverwing38
    silverwing38
    Ed the talking head is back...spewing his/her normal weekly nonsense about how Management is terrible, there's no interest in this company, etc...yet he/she continues to follow it and post every day. Hey Ed, why don't you get off the bottle for a few hours and compose some e-mails with your displeasure to EDAP Management or think of some questions for the upcoming quarterly conference call....can't wait to hear you relay all of your displeasure with the company on the quarterly call Wednesday.
  • m
    monday
    monday
    Just bought another 2000 shares at $2.57. At this price , you just can't lose!! shorts are having a hard time covering those 700000 shares before earnings!!
  • s
    silverwing38
    silverwing38
    Poor Ed the talking head must be getting desperate with all of his posts lately. He's either not picking up enough cheap shares or he can't unload his shorts. His desperate posts are always the same. As if anyone on this board can do anything about Management.
  • J
    John
    John
    Profound vs edap
    Profound market cap $66m, edap $75m
    Profound cash by 3/31, $16.9m, edap $21.7m
    Profound revenue last Q $0.6m( pure HIFU), edap $9.6m (HIFU 2.5m)
    Profund net loss last Q $4.1m, edap loss $0.3m
    Profund MRI real time guided HIFU prostate cancer fda trial expected finished around Nov 2018. Fda approve the earliest maybe second half of 2019.
    Edap is collecting focal-1 data now. And Ablatherm is fda approved.
    profund only has single digit installation sites worldwide(less than 5, mainly in Europe)and edap hundred of sites
    Profund technology MRI real time guide better than edap's MRI ported then combine with real-time ultrasound guided, but HIFU technology edap has proven over 20 years experiences and profund is a new player.
    Profund real time MRI makes its device none portable, each site must own one, Edap Ablatherm focal-1 easy portable. And price considering profund integated with MRI so price will be higher than edap. And even real time MRI guided, profund patient still need first MRI biopsy. Edap also need MRI biopsy first, and MRI result can be used to ported to focal-1 for treatment plan.
    Profund recently acquired Philip MRI-HIFU business for $6m ( share exchange, no cash transaction). I guess this tell us several things, Philip doesn't think its MRI-HIFU for prostate cancer treatment better than profund device (Philip had already did fda trail several years ago). Of course someone will argue that probably Philip thinks HIFU market for prostate cancer is too small, but considering the invasive factor and outpatient procedures and highly welcomed HIFU in Europe, obviously this is not the case.
    Secondly Philip sell its unit to profund by share exchange instead of cash, which means Philip think profund $66m market cap can justify its value.
    So conclusion for a $75m market cap, either edap is extremely under valued or profund is highly overvalued. But based on Philip's position, it seems edap should be double or triple its valuation event with current financial results.
  • H
    Horowitz
    Horowitz

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • E
    Ed
    Ed
    Even at this toilet-bowl level, there's not a whit of interest in this pile of dung. We're virtually assured of another dismal quarterly report in the long line of failure by this sad, incompetent management. Probably hit 2 by the end of next week.
  • E
    Ed
    Ed
    These toadies have nothing to cling to as far as this failed management is concerned. The FDA is just ignoring them, they continue to blunder and all they can do is assign the poor toady fool to try to obfuscate. But of course this mess is long beyond that now. We are sure to get another miserable report with the guarantee of many more to come. This management has so utterly failed. The oboy has to go.
  • E
    Ed
    Ed
    Just continues to fall and all the poor toady fool can think to do is attack me. What utter desperation!
  • A
    Anonymous
    Anonymous
    This smells bad. Why aren't they making good money in Europe?
  • E
    Ed
    Ed
    Blundering, incompetent, no-credibility, desperate management. Long-term failures. They should long ago have exited. End of story.
  • B
    Bert
    Bert
    Ed, whining on this board can't get rid of management. If your intent is to truly get rid of management, go email Edap everyday, go to the media, or stand outside their offices and protest. We all know your intent isn't to get rid of management, it's to bring the price lower. Take it to $2, I'll buy some more and profit again. Thanks buddy.
  • E
    Ed
    Ed
    You have to love the ones who insist that this can't go any lower from here regardless of earnings. They are the ones who were insisting it couldn't go lower when it was 5, then 4 then 3. This management has utterly failed, has no credibility and are not at risk as far as the stock price is concerned. And they have demonstrated complete contempt for shareholders.
  • F
    Frank
    Frank
    May dump soon. Need to buy more ovit.
  • E
    Ed
    Ed
    This thing with even halfway competent and credible management would now be at least 6; with able management it would be well above 10. Walk away from an investment that is in the toilet because of incompetent, long-term failed management? No way, Jose. I want this to attain the level and success that we all know we should have had at the very least a couple of years ago.
  • A
    Anonymous
    Anonymous
    This is a complete disaster without a hope until management is tossed. They don't have a clue and never have had.
  • A
    Anonymous
    Anonymous
    Can this get any worse? Who can defend this performance except for the board idiot.
  • d
    dave
    dave
    Unbelievable, a new, much improved procedure for treating cancer and these morons can't even sell it, even with thousands of successful cases and years of experience.
  • A
    Anonymous
    Anonymous
    The last thing these guys want to do is be forthcoming. We'll get the usual report headed by the fact that some sales category has increased over the last quarter or the year ago one but that figure itself will be in the two million range in other words puny. And the loss of two cents a share will be offset by the warrant mess gain of a dime a share. And they'll go on their merry way like this for another few years.
  • E
    Ed
    Ed
    Here's a suggestion for management and the PR firm:
    report operating earnings as the title and first datum of the quarterly report next week. The customary warrant accounting after a stock dive always leads a few to believe there was a significant profit and they buy raising the price for a day or so only to realize they were duped. Although you best interests are generally to obfuscate as much as you can to try to cover your failures, in this case I don't think you really benefit for anything longer than a morning and ultimately the general confusion and mishmash that is you usual report just comes back to bite you.
  • N
    Nick
    Nick
    This Share Price is a joke. No reason it is this low other than someone playing games and controlling this. No bad news, and low volume.